JCR Pharmaceuticals to Showcase at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT)
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 30 2025
0mins
Should l Buy ?
Source: Newsfilter
JCR Pharmaceuticals Presentation: JCR Pharmaceuticals will present non-clinical data on its JUST-AAV gene therapy platform at the ESGCT 32nd Annual Congress in Seville, Spain, from October 7-10, 2025.
JUST-AAV Technology: The JUST-AAV platform utilizes modified AAV vectors with enhanced targeting capabilities for specific tissues, aiming to improve delivery and reduce off-target effects in gene therapy applications.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
